Cover Image
市場調查報告書

RuiYi Inc. - 產品平台分析

RuiYi Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 309671
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
RuiYi Inc. - 產品平台分析 RuiYi Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月21日 內容資訊: 英文 25 Pages
簡介

RuiYi Inc.(元Anaphore)提供了開發生物學治療藥的醫療保健市場。該公司產品有用於治療慢性風濕病的單株抗體,以及治療纖維性代謝性疾病的候補藥等。此外更與Genor Biopharm合作,開發自體免疫疾病及癌症的治療法。

本報告提供RuiYi Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

RuiYi Inc.的基本資料

RuiYi Inc.概要

  • 主要資訊
  • 企業資料

RuiYi Inc.:R&D概要

  • 主要的治療範圍

RuiYi Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

RuiYi Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

RuiYi Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

RuiYi Inc.:藥物簡介

  • RYI-008
  • Monoclonal Antibody-1 for Undisclosed Indication
  • Monoclonal Antibody-2 for Undisclosed Indication
  • Monoclonal Antibody-3 for Undisclosed Indication
  • RYI-018

RuiYi Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

RuiYi Inc.:最近的開發平台趨勢

RuiYi Inc.:暫停中的計劃

RuiYi Inc.:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07681CDB

Summary

Global Markets Direct's, 'RuiYi Inc. - Product Pipeline Review - 2015', provides an overview of the RuiYi Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RuiYi Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of RuiYi Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of RuiYi Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the RuiYi Inc.'s pipeline products

Reasons to buy

  • Evaluate RuiYi Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of RuiYi Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the RuiYi Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of RuiYi Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of RuiYi Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of RuiYi Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RuiYi Inc. Snapshot
    • RuiYi Inc. Overview
    • Key Information
    • Key Facts
  • RuiYi Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • RuiYi Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • RuiYi Inc. - Pipeline Products Glance
    • RuiYi Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • RuiYi Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • RuiYi Inc. - Drug Profiles
    • RYI-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RYI-018
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RYI-028
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RuiYi Inc. - Pipeline Analysis
    • RuiYi Inc. - Pipeline Products by Target
    • RuiYi Inc. - Pipeline Products by Molecule Type
    • RuiYi Inc. - Pipeline Products by Mechanism of Action
  • RuiYi Inc. - Recent Pipeline Updates
  • RuiYi Inc. - Dormant Projects
  • RuiYi Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RuiYi Inc., Key Information
  • RuiYi Inc., Key Facts
  • RuiYi Inc. - Pipeline by Indication, 2015
  • RuiYi Inc. - Pipeline by Stage of Development, 2015
  • RuiYi Inc. - Monotherapy Products in Pipeline, 2015
  • RuiYi Inc. - Phase I, 2015
  • RuiYi Inc. - Preclinical, 2015
  • RuiYi Inc. - Discovery, 2015
  • RuiYi Inc. - Pipeline by Target, 2015
  • RuiYi Inc. - Pipeline by Molecule Type, 2015
  • RuiYi Inc. - Pipeline Products by Mechanism of Action, 2015
  • RuiYi Inc. - Recent Pipeline Updates, 2015
  • RuiYi Inc. - Dormant Developmental Projects,2015
  • RuiYi Inc., Other Locations

List of Figures

  • RuiYi Inc. - Pipeline by Top 10 Indication, 2015
  • RuiYi Inc. - Pipeline by Stage of Development, 2015
  • RuiYi Inc. - Monotherapy Products in Pipeline, 2015
  • RuiYi Inc. - Pipeline by Top 10 Target, 2015
  • RuiYi Inc. - Pipeline by Top 10 Molecule Type, 2015
  • RuiYi Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top